Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
Pfizer doubles down on PD-L1 conjugates
PF-08046037 joins PF-08046054 in clinical development.
Avistone’s Met challenge
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
Crispr moves ahead in GPC3
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
Mersana faces the inevitable
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
